Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in California: - AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Los Angeles General Medical Center — Los Angeles, California
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in California: - Fremont - Rideout Cancer Center — Marysville, California
- VA Palo Alto Health Care System — Palo Alto, California
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in California: - Research Site — Duarte, California
- Research Site — Fullerton, California
- Research Site — La Jolla, California
- Research Site — Los Alamitos, California
- Research Site — Orange, California
Phase 3 Recruiting Industry
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in California: - Site 82 — Duarte, California
- Site 25 — La Jolla, California
- Site 173 — Orange, California
- Site 28 — Palo Alto, California
- Site 127 — Sacramento, California
Phase 3 Recruiting Industry
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in California: - Providence St Jude Medical Center — Fullerton, California
- Scripps Health — La Jolla, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California, Los Angeles UCLA — Los Angeles, California
- Valkyrie Clinical Trials Murrieta — Murrieta, California
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in California: - Site 36 — La Jolla, California
- Site 27 — Los Angeles, California
- Site 16 — Palo Alto, California
Phase 3 Recruiting Industry
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in California: - GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Solvang, California
- GSK Investigational Site — Stockton, California
- GSK Investigational Site — Torrance, California
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in California: - University of California Los Angeles — Los Angeles, California
Phase 3 Recruiting Network
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in California: - City of Hope Corona — Corona, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope at Irvine Lennar — Irvine, California
Phase 3 Recruiting Industry
This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Sites in California: - City of Hope — Duarte, California
- University of California at San Diego Moores Cancer Center — La Jolla, California
- Memorial Radiation Oncology Medical Group Laguna Hills — Laguna Hills, California
- UCLA Hematology Oncology — Los Angeles, California
- Hoag Memorial Hospital — Newport Beach, California
Phase 2, Phase 3 Recruiting Industry
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …
Sponsor: BioNTech SE
NCT ID: NCT04534205
Sites in California: - California Research Institute — Los Angeles, California
- UCLA Cancer Care — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Sites in California: - Helios CR Inc./RadNet — Cerritos, California
- City of Hope National Cancer Center — Duarte, California
- Hoag Memorial Hospital — Irvine, California
- UCLA — Los Angeles, California
- Stanford University — Stanford, California
Phase 3 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…
Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Sites in California: - Providence Medical Foundation — Fullerton, California
- Univ of California Irvine College of Medicine — Orange, California
Phase 2, Phase 3 Recruiting Industry
Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…
Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in California: - City of Hope National Medical Center — Duarte, California
Phase 2, Phase 3 Recruiting Academic/Other
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of…
Sponsor: Andrei Iagaru
NCT ID: NCT05891769
Sites in California: - Stanford Hospital and Clinics — Stanford, California
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
- Los Angeles General Medical Center — Los Angeles, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Bellflower — Bellflower, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Kaiser Permanente Los Angeles Medical Center — Los Angeles, California
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …
Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
Phase 2 Recruiting NIH
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07195734
Sites in California: - USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Sutter Medical Center Sacramento — Sacramento, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
Phase 2 Recruiting NIH
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in California: - Kaiser Permanente Dublin — Dublin, California
- Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente Fresno Orchard Plaza — Fresno, California
- Kaiser Permanente-Fresno — Fresno, California
- Keck Medicine of USC Koreatown — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Children's Hospital Los Angeles — Los Angeles, California
- Valley Children's Hospital — Madera, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in California: - University of California Irvine Chao Family Comprehensive Cancer Center — Irvine, California
- University of San Diego Moores Cancer Center — La Jolla, California
- UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in California: - UCSD — La Jolla, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sharp Healthcare — San Diego, California